secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zai Lab Ltd (ZLAB)
CIK:        0001704292
Form:       8-K
Filed at:   2021-12-22T23:59:59+00:00
Accession:  0001193125-21-364991
Event type: leadership
Sentiment:  positive
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zai Lab promotes Harald Reinhart to President and Head of Global Development
----------------------------------------------------------------------------

- Harald Reinhart, M.D., promoted from CMO to President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases
- Reinhart received a special equity grant of 30,000 restricted share units, with 50% vesting immediately and 50% on Dec 31, 2022
- Base salary and target bonus for 2022 and 2021 bonus increased to be commensurate with other executive officers
- Reinhart has been with Zai Lab since inception, first as advisor and since 2017 as CMO
- Prior to Zai Lab, he served at Shionogi U.S., Novartis, and Bayer Corp with broad clinical development experience

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704292/000119312521364991/0001193125-21-364991-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704292/000119312521364991/d278574d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-364991

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer